Surface marker abnormalities in myelodysplastic syndromes

Haematologica

Volumn 83, Issue 12, 1998, Pages 1104-1115

  Tarek Elghetany, M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Flow cytometry; Monocytes; Myelodysplastic syndromes; Neutrophils; Surface antigens

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; HLA DR ANTIGEN; MEMBRANE ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; MONOCYTE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PROGNOSIS; REVIEW;

ANTIGENS, CD; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; BONE MARROW CELLS; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; TUMOR MARKERS, BIOLOGICAL;

EID: 0032428533     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Cooperative Group: Protocols for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
2. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
3. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
4. Elghetany MT, Hudnall SD, Gardner FH. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica 1997; 82:21-4.
5. Elghetany MT, Peterson B, MacCallum J, et al. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: A common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res 1997; 21:801-6.
6. Elghetany MT, Peterson B, MacCallum J, et al. Double esterase staining and other neutrophilic granule abnormalities in 237 patients with the myelodysplastic syndrome studied by the Cancer and Leukemia Group B. Acta Haematol 1998; 100:13-6.
7. Mazzone A, Porta C, Fossati G, Gritti D, Mazzucchelli I, Ricevuti G. Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Leuk Lymphoma 1996; 23:267-75.
8. Moretti S, Lanza F, Spisani S, et al. Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma 1993; 13:471-7.
9. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996; 20:881-90.
10. Kristensen JS. Immunophenotyping in acute leukaemia, myelodysplastic syndromes and hairy cell leukaemia. Danish Med Bull 1994; 41:52-65.
11. Jennings CD, Foon, KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90:2863-92.
12. Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:485-99.
13. Kanter-Lewensohn L, Hellstrom-Lindberg E, Kock Y, Elmhorn-Rosenborg A, Ost A. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Eur J Haematol 1996; 56:124-9.
14. Razak K, Newland AC. Induction of CD13 expression of fresh myeloid leukaemia: Correlation of CD13 expression with aminopeptidase-N activity. Leuk Res 1992; 16:625-30.
15. Kuijpers TW, Tool ATJ, van der Schoot CE, et al. Membrane surface antigen expression on neutrophils: A reappraisal of the use of surface markers for neutrophil activation. Blood 1991; 78:1105-11.
16. Huizinga TWJ, van der Schoot CE, Jost C, et al. The Pl-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988; 33:667-9.
17. Fearon DT, Collins LA. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol 1983; 130:370-5.
18. Werfel T, Sonntag G, Weber MH, Gotze O. Rapid increases in the membrane expression of neutral endopeptidase (CD10), aminopeptidase N (CD13), tyrosine phosphatase (CD45), and Fcγ-RIII (CD16) upon stimulation of human peripheral leukocytes with human C5a. J Immunol 1991; 147:3909-14.
19. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11 b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 1993; 43:165-71.
20. Guyotat D, Campos L, Thomas X, et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 1990; 34:26-31.
21. Terstappen LWMM, Hollander A, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol 1990; 48:138-48.
22. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989; 46:183-219.
23. Fleitt HB, Wright SD, Durie CJ, Valinsky JE, Unkeless JC. Ontogeny of Fc receptors and complement receptor (CR3) during human myeloid differentiation. J Clin Invest 1984; 73:516-25.
24. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997; 89:3503-21.
25. Bernier M, Jacquy C, Massy M, et al. Myelomonocytic antigen abnormalities on neutrophils and monocytes in myelodysplastic syndromes. Leuk Res 1994; 18(Suppl):5.
26. Ohsaka A, Saionji K, Watanabe N, et al. Complement receptor type 1 (CR1) deficiency on neutrophils in myelodysplastic syndrome. Br J Haematol 1994; 88: 409-12.
27. Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 1997; 98:108-13.
28. Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol 1993; 84:428-35.
29. Anderson RW, Volsky DJ, Greenberg B, et al. Lymphocyte abnormalities in preleukemia-I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBVreceptors. Leuk Res 1983; 7:389-95.
30. Terstappen LWMM, Safford M, Loken MR. Flow cytometric analysis of human bone marrow III. Neutrophil maturation. Leukemia 1990; 4:657-63.
31. Kansas GS, Muirhead MJ, Dailey MO. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 1990; 76:2483-92.
32. Bowen KL, Davis BH. Abnormal patterns of expression of CD16 (FcRγIII) and CD11b (CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol 1997; 3:292-8.
33. Ricevuti G, Mazzone A, Notario A. Definition of CD11a, b, c and CD 18 glycoproteins on chemotactically deficient granulocyte membranes in patients affected by myeloid disorders. Acta Haematol 1989; 81:126-30.
34. Mazzone A, Ricevuti G, Pasotti D, et al. The CD11/CD18 granulocyte adhesion molecules in myelodysplastic syndromes. Br J Haematol 1993; 83: 245-52.
35. Ricevuti G, Mazzone A, Pasotti D, Fossati G, Mazzucchelli I, Notario A. The role of integrins in granulocyte dysfunction in myelodysplastic syndrome. Leuk Res 1993; 17:609-19.
36. Galvani D, Dang Y, Watson F, et al. Combination of GM-CSF and cytosine in myelodysplasia results in improved neutrophil function. Acta Haematol 1992; 87:129-35.
37. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990; 75:1037-50.
38. Ball ED, McDermott J, Griffin JD, Davey FR, Davis R, Bloomfield CD. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood 1989; 73:1951-6.
39. th International Workshop on leukocyte differentiation antigens. Leukemia 1994; 8: 347-58.
40. Bordessoule D, Jones M, Gatter KC, Mason DY. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67. Br J Haematol 1993; 83:370-83.
41. Watson F, Dunbar D, Davies J. Neutrophil function and phenotype in myelodysplasia. Eur J Clin Invest 1988; 18:250.
42. Tanawattancharoen P, Molldrem J, Boccuni P, Kirby MR, Young NS, Dunn DE. Glycosylphosphatidyl-inositol-anchored protein-deficient cells in myelodysplasia. Blood 1997; 90(Suppl 1):202a.
43. Berg M, James, SP. Human neutrophils release the Leu-8 lymph node homing receptor during cell activation. Blood 1990; 76:2381-8.
44. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989; 10:423-8.
45. Krensky A, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ.The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: Cell surface antigens associated with CTL-target interactions. J Immunol 1983; 11:611-6.
46. Boyd AW, Dunn SM, Fecondo JV, et al. Regulation of expression of a human intercellular adhesion molecule (ICAM-1) during lymphohematopoietic differentiation. Blood 1989; 73:1896-903.
47. Maio M, Pinto A, Carbone A, et al. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood 1990; 76:783-90.
48. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 1981; 68:932-41.
49. Kerndrup G, Bendix-Hansen K, Pedersen B, Ellegaard J, Hokland P. Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data. Eur J Haematol 1988; 41:368-74.
50. Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986; 67:898-902.
51. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990; 74:270-6.
52. Bonde J, Meyer K, Kjervig Broe M, Hokland M, Turley H, Hokland P. Improved flow cytometric identification of myelopoiesis by the simultaneous labeling with CD13, CD14 and CD66 monoclonal antibodies. Br J Haematol 1996; 92:269-79.
53. Kwong YL, Lee CP, TK Chan, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol 1994; 102:30-5.
54. Baumann MA, Keller RH, McFadden PW, Libnoch JA, Patrick CW. Myeloid cell surface phenotype in myelodysplasia: Evidence for abnormal persistence of an early myeloid differentiation antigen. Am J Hematol 1986; 22:251-7.
55. Jensen IM, Hokland, P. The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br J Haematol 1994; 87:477-82.
56. Kerndrup G, Bendix-Hansen K, Pedersen B, Ellegaard J, Hokland P. 13-cis retinoic acid treatment of myelodysplastic syndromes. Leuk Res 1987; 11:7-16.
57. Oertel J, Kleiner S, Huhn D. Immunotyping of blasts in refractory anaemia with excess of blasts. Br J Haematol 1993; 84:305-9.
58. Oertel J, Oertel B, Beyer J, Huhn D. CD 34 immunotyping of blasts in myelodysplasia. Ann Hematol 1994; 68:77-80.
59. Clark RE, Hoy TG, Jacobs A. Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes. J Clin Pathol 1985; 38:301-4.
60. Elghetany MT, Sullivan AK, Kurec AS, et al. The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells. Am J Clin Pathol 1992; 98:430-6.
61. Kerr M, Stocks SC. The role of CD 15-(Lex)-related carbohydrates in neutrophil adhesion. Histochem J 1992; 24:811-26.
62. Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H. Further characterization of human myeloid antigens (gp160, 95; gp67). Investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol 1988; 69:163-71.
63. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984; 8: 521-34.
64. Andreasen RB, Killmann SA, Olsson, L. A monoclonal antibody (Nat-9 II :3F-6F) that identifies a differentiation antigen on human myeloid cells. Leuk Res 1985; 9:1161-70.
65. Duperray C, Boiron JM, Boucheix C, et al. The CD24 antigen discriminates between pre-B and B cells in human bone marrow. J Immunol 1990; 145:3678-83.
66. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133:157-65.
67. Sullivan SA, Marsden KA, Lowenthal RM, Jupe DM, Jones ME. Circulating CD34+ cells: an adverse prognostic factor in the myelodysplastic syndromes. Am J Hematol 1992; 39:96-101.
68. Soligo DA, Oriani A, Annalora C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994; 46:9-17.
69. Oriani A, Annaloro C, Soligo D, Pozzoli E, Cortelezzi A, Deliliers GL. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 1996; 92:360-4.
70. Lanza F, Castagnari B, Rigolin G, et al. Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells. Leukemia 1997; 11:1700-10.
71. Macedo A, Orfao A, Martinez A, et al. Immunophenotype of c-kit cells in normal bone marrow: implications for the detection of minimal residual disease in AML Br J Haematol 1995; 89:338-41.
72. Backx B, Broeders L, Hoefsloot LH, Wognum B, Lowenberg B. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia 1996; 10:466-72.
73. Molica S, Mannella A, Dattilo A, et al. Differential expression of BCL-2 oncoprotein and FAS antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Haematologica 1996; 81:302-9.
74. Miyawaki T, Uehara T, Nibu R, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149:3753-8.
75. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84:1201-8.
76. Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996; 88:1122-3.
77. DiGiuseppe JA, LeBeau P, Augenbraun J, Borowitz MJ. Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. Am J Clin Pathol 1996; 106:345-51.
78. Bouscary D, DeVos J, Guesnu M, et al. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11:839-45.
79. Kliche KO, Andreef M. High expression of phosphatidylserine in MDS, secondary AML and normal progenitors: comparison with primary AML. Blood 1997;90(Suppl 1):202a.
80. Huelin C, Gonzalez M, Pedrinachi S, et al. Distribution of the CD45R antigen in the maturation of lymphoid and myeloid series: the CD45R negative phenotype is a constant finding in T CD4 positive lymphoproliferative disorders. Br J Haematol 1988; 69:173-9.
81. Schiavone EM, Lo Pardo C, Noto RD, et al. Expression of the leucocyte common antigen (LCA, CD45) isoforms RA and RO in acute haematological malignancies: possible relevance in the definition of new overlap points between normal and leukaemic haemopoiesis. Br J Haematol 1995; 91:899-906.
82. Iwase O, Aizawa S, Kuriyama Y, Yaguchi M, Nakano M, Toyama K. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. Ann Hematol 1995; 71: 293-9.
83. Pirruccello SJ, Johnson DR: Reagents for flow cytometry: monoclonal antibodies and hematopoietic cell antigens. In Keren DF, Hanson CA, Hurtubise PE, eds. Flow Cytometry and Clinical Diagnosis. Chicago: ASCP Press, 1994. p. 56-78.
84. Clark P, Normansell DE, Innes DJ, Hess CE. Lymphocyte subsets in normal bone marrow. Blood 1986; 67:1600-6.
85. Maciejewski J, Hibs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 1994; 22:1102-10.
86. Takeshita KS, Ohnishi K, Ohno R. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells. Br J Haematol 1996; 93:18-21.
87. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8:998-1004.
88. Sonneveld P, van Dongen JJM, Hagemeijer A, et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993; 7:963-9.
89. List AF, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell pheno-type. Br J Haematol 1991; 78:28-34.
90. Weemaes CMR, Preijers F, deVaan GAM, Bakkeren JAJM, Klasen IS, Haraldsson A. CD4 deficiency in myelodysplastic syndrome with monosomy 7. Eur J Pediatr 1996; 155:96-8.
91. Symeonidis A, Kourakli A, Katevas P, et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: Correlation with the FAB classification and prognosis. Eur J Haematol 1991; 47:277-81.
92. Carpani G, Rosti A, Vozzo N. T Lymphocyte subpopulations in myelodysplastic syndromes. Acta Haematol 1989; 81:173-5.
93. Colombat PH, Renoux M, Lamagnere JP, Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer 1988; 61:1075-81.
94. Ayanlar-Batuman O, Shevitz J, Traub UC, Murphy S, Sajewski D. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. Blood 1987; 70:494-500.
95. Merchav S, Nagler A, Silvian I, Carter A, Tatarsky I, Spira G. Immunoglobulin synthesis in myelodysplastic syndromes: normal B-cell and immunoregulatory T-cell functions. Clin Immunol Immunopathol 1987; 42:195-201.
96. Yokose N, Ogata K, Ito T, et al. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Leuk Res 1994; 18:777-82.
97. Woodlock TJ, Sheshi B, Sham RL, Cyran EM, Bennett JM. Use of cell surface antigen phenotype in guiding therapeutic decision in chronic myelomonocytic leukemia. Leuk Res 1994; 18:173-81.
98. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33:150-62.
99. Hilbe WE, Schmid C, Starz I, et al. Bone marrow lymphocyte subsets in myelodysplastic syndromes. J Clin Pathol 1994; 47:505-7.
100. Aso T, Okamura T, Shibuya T, Harada M, Niho Y, Kikiuchi M. A case of hybrid phenotypic chronic myelomonocytic leukemia transformed from aplastic anemia. Jpn J Med 1989; 28:385-90.
101. Ogata KHF, Yokose N, An E, et al. Defective natural killer (NK) cell-mediated cytotoxicity does not imply clonal involvement on NK cells in myelodysplastic syndrome. Br J Haematol 1994; 87:396-8.
102. Mann KP, DeCastro CM, Liu J, Moore JO, Gibner SH, Traweek ST. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1996; 107:653-60.
103. Hattori H, Machii T, Ueda E, Shibano M, Kageyama T, Kitani T. Increased frequency of somatic mutations at glycophorin A loci in patients with aplastic anaemia, myelodysplastic syndrome and paroxysmal nocturnal haemoglobinuria. Br J Haematol 1997; 98:384-91.
104. Kuiper-Kramer PA, Huisman CMS, Van derMolen-Sinke J, Abbes A, Van Eijk HG. The expression of transferrin receptors on erythroblasts in anaemia of chronic disease, myelodysplastic syndromes and iron deficiency. Acta Haematol 1997; 97:127-31.
105. Berndt MC, Kabral A, Grimsley P, Watson N, Robertson TI, Bradstock KF. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 1988; 68:97-101.